Mechanismen der Apoptoseregulation durch TRAIL-Rezeptor 4 in primären humanen Hepatozyten und hepatozellulären Karzinomen

• Antragsteller: Privatdozent Dr. Tom Ganten
• Fachliche Zuordnung: Hämatologie, Onkologie
• Förderung: Förderung von 2004 bis 2007
• Projektkennung: Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 5423371

• Erstellungsjahr: 2008

Zusammenfassung der Projektergebnisse

Keine Zusammenfassung vorhanden

Projektbezogene Publikationen (Auswahl)

• Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 2004; 11 Suppl 1:S86-96
  Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, Krammer PH, Walczak H
  
• Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 2005;42:588-97
  Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K, Walczak H
  
• Transforming growth factor beta can mediate apoptosis via the expression of TRAIL in human hepatoma cells. Hepatology 2005:42:183-92
  Herzer K, Ganten TM, Schulze-Bergkamen H, Grosse-Wilde A, Koschny R, Krammer PH, Walczak H
  
• Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 2006;12:2640-6
  Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Buchler P, Haas TL, Schader MB, Untergasser A, Stremmel W, Walczak H
  
• The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab. Cytotherapy 2006:8:13-23
  Kornacker M, Verneris M, Kornacker B, Ganten T, Scheffold C, Negrin R
  
• Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res 2007;13:3403- 12
  Koschny R, Holland H, Sykora J, Haas TL, Sprick MR, Ganten TM, Krupp W, Bauer M, Ahnert P, Meixensberger J, Walczak H
  
• Bortezomib-Mediated Up-Regulation of TRAIL-R1 and TRAIL-R2 Is Not Necessary for but Contributes to Sensitization of Primary Human Glioma Cells to TRAIL. Clin Cancer Res 2007;13:6541-2
  Koschny R, Sykora J, Walczak H, Ganten TM, Haas TL, Sprick MR, Holland H, Ahnert P, Krupp W, Meixensberger J, Bauer M
  
• Cytogenetic and molecular biological characterization of an adult medulloblastoma. Cancer Genet Cytogenet 2007:178:104-13
  Holland H, Koschny R, Krupp W, Meixensberger J, Bauer M, Schober R, Kirsten H, Ganten TM, Ahnert P
  
• Helicobacter pylori-induced apoptosis in T cells is mediated by the mitochondrial pathway independent of death receptors. Eur J Clin Invest 2007:37:117-25
  Ganten TM, Aravena E, Sykora J, Koschny R, Mohr J, Rudi J, Stremmel W, Walczak H
  
• Regulation of enterocyte apoptosis by acyl-CoA synthetase 5 splicing. Gastroenterology 2007; 133:587-98
  Gassler N, Roth W, Funke B, Schneider A, Herzog F, Tischendorf JJ, Grund K, Penzel R, Bravo IG, Mariadason J, Ehemann V, Sykora J, Haas TL, Walczak H, Ganten T, Zentgraf H, Erb P, Alonso A, Autschbach F, Schirmacher P, Knuchel R, Kopitz J
  
• The promise of TRAIL-potential and risks of a novel anticancer therapy. J Mol Med 2007;85:923-35
  Koschny R, Walczak H, Ganten TM
  
• TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 2007;45:649- 58
  Koschny R, Ganten TM, Sykora J, Haas TL, Sprick MR, Kolb A, Stremmel W, Walczak H